ClinicalTrials.gg
CompletedNCT00150293Updated Mar 5, 2015

Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

A Phase 3 interventional study of Pregabalin in Seizure Disorder, Partial, sponsored by Pfizer. Completed at 84 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-05.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
337
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies testing pregabalin in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Pregabalin · Epilepsies, Partial.

Enrollment
6th of 18
337 · median 244
Started
2002
with 1 other
Phase 3
12 of 18
none open now
Registered
6th of 18
by date
Lead sponsor
7 of 18
Pfizer

Among the 18 studies testing pregabalin in Epilepsies, Partial, this one is the 6th largest by enrollment, is one of 2 that started in 2002, is one of 12 in phase 3, and was the 6th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing pregabalin in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing pregabalin in Epilepsies, Partial as a file.
02

Study summary

To determine long-term safety and efficacy of pregabalin in patients with partial seizures.

03

Conditions studied

  • Seizure Disorder, Partial

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have met the inclusion criteria for preceding double-blind study
  • Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion criteria

Exclusion Criteria:

  • Cannot be pregnant or considering becoming pregnant during the course of the study.
  • Cannot be receiving any concomitant medication that could alter the effectiveness of the pregabalin response or affect seizure frequency.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
337 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Safety Efficacy

07

Study locations

84 sites
  • Pfizer Investigational Site
    Deakin, Australian Capital Territory 2600, Australia
  • Pfizer Investigational Site
    Camperdown, New South Wales 2050, Australia
  • Pfizer Investigational Site
    Chastwood, New South Wales 2067, Australia
  • Pfizer Investigational Site
    Cairns, Queensland 4870, Australia
  • Pfizer Investigational Site
    Maroochydore, Queensland 4558, Australia
  • Pfizer Investigational Site
    Footscray, Victoria 3011, Australia
  • Pfizer Investigational Site
    Parkville, Victoria 3050, Australia
  • Pfizer Investigational Site
    Perth, Western Australia 6001, Australia
  • Pfizer Investigational Site
    Auenbruggerplatz 22, A-8035 GRAZ, Austria
  • Pfizer Investigational Site
    Graz, 8020, Austria
  • Pfizer Investigational Site
    Innsbruck, A6020, Austria
  • Pfizer Investigational Site
    Linz, 4020, Austria
  • Pfizer Investigational Site
    Wien, 1220, Austria
  • Pfizer Investigational Site
    Leuven, 3000, Belgium
  • Pfizer Investigational Site
    Calgary, Alberta T2N 2T9, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T5G 0B7, Canada
  • Pfizer Investigational Site
    Penticton, British Columbia V2A 4V8, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3H 3A7, Canada
  • Pfizer Investigational Site
    Barrie, Ontario L4M 4S5, Canada
  • Pfizer Investigational Site
    London, Ontario N6A 5A5, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K1L 8L6, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5T 2S8, Canada
  • Pfizer Investigational Site
    Windsor, Ontario N8X5A6, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H1T 2M4, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2L 4M1, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H3A 2B4, Canada
  • Pfizer Investigational Site
    Regina, Saskatchewan S4T 1A5, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Pfizer Investigational Site
    Quebec, G1J 1Z4, Canada
  • Pfizer Investigational Site
    Ulm, BW 89081, Germany
  • Pfizer Investigational Site
    Berlin, BE10362, Germany
  • Pfizer Investigational Site
    Bernau, 16321, Germany
  • Pfizer Investigational Site
    Bonn, 53127, Germany
  • Pfizer Investigational Site
    Dresden, 01307, Germany
  • Pfizer Investigational Site
    Erlangen, 91054, Germany
  • Pfizer Investigational Site
    Essen, 45147, Germany
  • Pfizer Investigational Site
    Frankfurt, HE 60528, Germany
  • Pfizer Investigational Site
    Freiburg, 79106, Germany
  • Pfizer Investigational Site
    Goettingen, D-37075, Germany
  • Pfizer Investigational Site
    Hamburg, D-22337, Germany
  • Pfizer Investigational Site
    Mainz, 55101, Germany
  • Pfizer Investigational Site
    Muenchen, 81377, Germany
  • Pfizer Investigational Site
    AE Breda, 4836, Netherlands
  • Pfizer Investigational Site
    Blaricum, 1261 AN, Netherlands
  • Pfizer Investigational Site
    Ve Heeze, 5591, Netherlands
  • Pfizer Investigational Site
    Bialystok, 15-276, Poland
  • Pfizer Investigational Site
    Bydgoszcz, 85-826, Poland
  • Pfizer Investigational Site
    Choroszcz, 16-070, Poland
  • Pfizer Investigational Site
    Gdansk, 80-211, Poland
  • Pfizer Investigational Site
    Gdansk, 82-803, Poland
  • Pfizer Investigational Site
    Grudziadz, 86-300, Poland
  • Pfizer Investigational Site
    Katowice, 46-645, Poland
  • Pfizer Investigational Site
    Krakow, 31-112, Poland
  • Pfizer Investigational Site
    Lublin, 20-718, Poland
  • Pfizer Investigational Site
    Mosina, 62-050, Poland
  • Pfizer Investigational Site
    Olsztyn, 10-561, Poland
  • Pfizer Investigational Site
    Plock, 09-402, Poland
  • Pfizer Investigational Site
    Poznan, 60-780, Poland
  • Pfizer Investigational Site
    Poznan, 61-285, Poland
  • Pfizer Investigational Site
    Torun, 87-100, Poland
  • Pfizer Investigational Site
    Warsaw, 00-909, Poland
  • Pfizer Investigational Site
    Warsaw, 02-957, Poland
  • Pfizer Investigational Site
    Warszawa, 00-909, Poland
  • Pfizer Investigational Site
    Warszawa, Poland
  • Pfizer Investigational Site
    Coimbra, 3000-075, Portugal
  • Pfizer Investigational Site
    Porto, 4099, Portugal
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Girona, 17007, Spain
  • Pfizer Investigational Site
    Granada, 18013, Spain
  • Pfizer Investigational Site
    Madrid, 28034, Spain
  • Pfizer Investigational Site
    Madrid, 28040, Spain
  • Pfizer Investigational Site
    Malaga, 29010, Spain
  • Pfizer Investigational Site
    Zaragoza, 50009, Spain
  • Pfizer Investigational Site
    Middlesborough, N. York TS5 5AZ, United Kingdom
  • Pfizer Investigational Site
    Washington, Tyne & Wear NE38 9JZ, United Kingdom
  • Pfizer Investigational Site
    Blackpool, FY3 8BP, United Kingdom
  • Pfizer Investigational Site
    Dundee, DD1 9SY, United Kingdom
  • Pfizer Investigational Site
    Glasgow, G11 6NT, United Kingdom
  • Pfizer Investigational Site
    Leeds, LS9 7TF, United Kingdom
  • Pfizer Investigational Site
    London, E1 1BB, United Kingdom
  • Pfizer Investigational Site
    Northampton, NN1 5BD, United Kingdom
  • Pfizer Investigational Site
    Wolverhampton, WV10 0QP, United Kingdom
  • Pfizer Investigational Site
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2002 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 8, 2005
Start
Mar 2002
Completion
Nov 2005
Last update
Mar 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Mar 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00150293
Lead sponsor
Pfizer
First posted
Sep 8, 2005
Start date
Mar 2002
Completion
Nov 2005
Last update
Mar 5, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion